Lin Elizabeth Yeu 4

What Happened

• Lin Elizabeth Yeu, Chief Medical Officer of Tarsus Pharmaceuticals (TARS), received two equity awards reported on Form 4 for the reporting period 2026-03-05 and filed 2026-03-09.
• The filing shows acquisition (grant) of 27,310 derivative option shares (acquired at $0.00) and 17,161 Restricted Stock Units (RSUs) (acquired at $0.00). No cash changed hands at grant; these are compensation/retention awards rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-03-05; Form 4 filed: 2026-03-09 (filed on the normal 2-business‑day timetable).
• Option grant: 27,310 derivative shares. Vesting: 25% on March 5, 2027, then 1/48th per month thereafter for 3 years (footnote F1).
• RSU grant: 17,161 RSUs (each RSU = right to one common share). Vesting: four equal annual installments on March 15 of 2027, 2028, 2029 and 2030 (footnote F3; F2 explains RSU = one share).
• Price shown: $0.00 for both entries (reflects grant/award reporting; exercise price for options not provided in the summary).
• Shares owned after the transaction: not specified in the information provided.
• Filing timeliness: filed on 2026-03-09 for a 2026-03-05 grant — appears timely (not marked late).

Context

• These are grant awards (transaction code A) tied to continued service; they vest over time and do not represent an immediate open‑market investment by the insider. Options require future vesting and (typically) exercise to convert to shares; RSUs convert to shares upon vesting.
• Such grants are common as executive compensation/retention and should be viewed as compensation events rather than direct signals of immediate insider buying or selling.